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ABSTRACT 
This research aims  to determine whether  SAG2 oral vaccine induced antibody response as high as 
that of parenteral vaccine (Rabisin and Rabivet Supra 92). The experimental design applied was randomized 
pre and post control group design with 4 treatments (oral SAG2 vaccine, parenteral rabisin, parenteral 
Rabivet Supra 92 and control without vaccination) and with 9 replication. As many as 36  kampung dogs 
used and the anti rabies antibody was determined by enzyme-linked immunosorbent assay (ELISA) at day 0, 
21, 56, 84, 119, and  147 post vaccination. The antibody titer induced by oral SAG2 vaccine raised more 
slowly but persisted longer than parenteral vaccine. On day 21 after vaccination, the average antibody 
titers induced by oral SAG2 vaccines (0.501 IU/ml) was still significantly lower than those induced by 
parenteral Rabisin (3.504 IU/ml) and Rabivet Supra92 (2.545 IU/ml). However, by day 119 after vaccination 
the average antibody titer induced by SAG2 oral vaccine (0.889 IU/ml) was significantly higher (p <0.05) as 
compared to those of parenteral  Rabisin (0.625 IU/ml) and Rabivet Supra 92 (0.223 IU/ml). The antibody 
response induced by SAG2 oral vaccine appears to persist longer than parenteral vaccines and it can 
therefore be used as an alternative vaccine to combat rabies in animals, especially for dogs kept in free 
range.  
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INTRODUCTION 
Rabies is a fatal zoonotic disease attacking all 
warm blooded animals including humans. At this time 
the rabies continues to spread and difficult to control, 
not only in developing country but also in developed 
countries. Until now, the methods used to control 
rabies are vaccination, mostly by parenteral routes.  
Parenteral vaccination route faces many problems 
when applied to dogs. Such problems cause difficulties 
in achieving vaccination coverage of greater than 70%. 
Recently oral vaccination has been recommended by 
the World Health Organization (WHO) and has been 
successfully used to eradicate rabies from many 
countries, especially for control of rabies in wild 
animals and dogs. Oral vaccines that have been 
guaranteed for its safety are the Rabies Virus 
Glycoprotein (VRG) and Street Alabama Dufferin Gif 2 
(SAG2). The use of oral vaccines in Indonesia is 
expected to improve vaccination coverage by more 
than 70% and its use in the field appears to be very 
practical as it does not require many vaccinators in the 
field, especially in wild animals and dogs that are kept 
removable and hard to catch. Up to now, research on 
the use of oral vaccines to control rabies in free range 
dog  in  Indonesia  has  not  been  conducted yet. It is  
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therefore necessary to conduct a study on the 
humoral antibody of dogs vaccinated with oral SAG2 
vaccines as comparison to those induced by parenteral 
rabisin and Rabivet Supra 92. 
 
METHODS 
Vaccines 
In this study, the vaccine used were oral dose of 
SAG2 rabies vaccine (Virbac, France),  parenteral  
Rabisin (Merial, France), and  parenteral Rabivet Supra 
92 (Pusvetma, Surabaya, Indonesia). They were all 
commercial vaccines. Th SAG2  vaccine was a 
modified-live rabies vaccine included in a bait for oral 
administration to kampung dogs. The rabies virus 
strain SAG2 was selected from SAD Bern-a subclone of 
a virus isolated from salivary glands of a rabid dog in 
1935- in two-step process of amino acid mutation 
(Lafay., et al. 1994). The vaccine liquid suspension is 
presented within a PVC/aluminium sachet, which is 
coated with an appetent matrix made of mineral fat, 
fish ingredients and tetracycline as a biomarker. The 
bait measures 4.9 cm x 4.4 cm x 1.5 cm and weights 28 
g. Rabisin was inactivated vaccine consisted of rabies 
virus glikoprotein (≥ 1 IU), 0.1 mg Thiomersal, 1.7 mg  
Aluminium (as hydroxide) with  the Lot number 
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L360155. Rabivet Supra 92 rabies was inactivated 
tissue culture vaccine with  butch number: Deptan RI 
D.06121430 VKC.1. 
 
Experimental animals  and vaccination procedures  
As many as 36 Kampung dogs aged 3 month  to 1 
year old)  were used in the study. They were randomly 
allocated into four groups: group A (n = 9 kampung 
dogs) was  vaccinated by Oral SAG2, group B (n = 9 
kampung dogs) was  vaccinated by Rabisin, group C (n 
= 9 kampung dogs) was vaccinated by Rabivet Supra 
92, and  group D (n = 9 kampung dogs) was not 
vaccinated and kept as controls.  Serum samples were 
collected from the dogs on days 0 (prior to 
vaccination) and on days 21, 56, 84, 119, and 147 post 
vaccination.  
 
Enzyme-linked immunosobent assay (ELISA) 
Antibody titer was determined by the enzym 
linked immunosorbent assay (ELISA) (PLATELIATM 
RABIES II KIT, ad usum veterinarium) according to 
manufacturer precedure described. In brief; 100 µl  
sera samples (diluted 1:100 in dilution buffer) were 
added into each well of ELISA plates coated with 
glycoprotein-rabies virus and incubated for 1 hour at 
37oC. After that, the wells were washed 3 times with 
ELISA wash buffer,  then 100 µl anti-canine IgG-horse 
radish peroxidase  was added into each weell and 
incubated at 37oC for 1 hour. Then, the wells were 
washed again (2 times) as above and 100 µl ABTS 
substrate was added and incubated at room 
temperature for 30 menutes. Stop solution was then 
added and absorbant  was recorded using ELISA 
reader at 450 nm. Antibody titer were calculated by 
comparing obsorbant of each sample with standard 
postive and negative samples and expressed in 
international units (IU).  
 
Experimental design and analysis data 
Experimenatl design applied in this study was 
completely randomized pre and post control group 
design consisted of 4 treatmets (A: oral SAG2 vaccine, 
B: parenteral rabisin, C: parenteral rabivet Supra 92, 
and D: without vaccination). Each treatment consisted 
of 9 replications. The data obtained were analysed by 
Analysis of Variances (Anova) and proceeded with 
Least Significant difference (LSD) if there were 
significant differences among treatment groups. 
 
RESULTS 
The antibody titer induced by oral SAG2 vaccine 
raised more slowly but persisted longer than 
parenteral vaccine. On day 21 after vaccination, the 
average antibody titers induced by oral SAG2 vaccines 
(0.501 IU/ml) was still significantly lower than those 
induced by parenteral Rabisin (3.504 IU/ml) and 
Rabivet Supra92 (2.545 IU/ml). However, by day 119 
after vaccination the average antibody titer induced 
by SAG2 oral vaccine (0.889 IU/ml) was significantly 
higher (p<0.05) compared to those of parenteral  
Rabisin (0.625 IU/ml) and Rabivet Supra 92 (0.223 
IU/ml). Mean Rabies Humoral Antibody Titres on day 0 
(before vaccination) and on days 21, 56, 84, 119 and 
147 after vaccination (before challange) were 
presented in Table 1 and Figure 1. 
Tabel 1 
Mean Rabies Humoral Antibody Titres on day 0 
(before vaccination) and on days 21, 56, 84, 119 and 
147 after vaccination 
Days Mean rabies antibody after vaccination A B C D 
21 0,501* c 3,504  a 2,545  b 0,125 
56 1,406 a 2,918 a 1,940 a 0,125 
84 1,389 a 1,616 a 0,797 a 0,125 
119 0,889 a 0,625 b 0,223 c 0,125 
147 0,675 a 0,408 a 0,178 b 0,125 
Mean -0,03 0,62 0,47 - 
A = Oral SAG2, B = Rabisin, C = Rabivet Supra 92, D = Control, 
same alphabetic indicates insignificant (p > 0.05). 
 
 
Figure 1 
Mean antibody titer was vaccinated by oral SAG2, 
parenteral Rabisin and Rabivet Supra 92 on  at days 0, 
21, 56, 84, 119 and 147 after vaccination 
 
DISCUSSION 
In this study, rabies virus antibodies examined by 
ELISA test and titer is measured in international units 
(IU) per ml. Antigen used in ELISA test is part of the 
rabies virus glycoprotein, so the result is more specific 
because it reflects the titer of antibodies against the 
rabies virus proteins that play an important role in 
neutralization. As it is known that rabies virus has 
some kind protein, such as glycoprotein (G), 
nucleoprotein (N), phosphoprotein (P), and matrix 
(M). Glycoprotein (G) is an important protein that 
plays a role in attachment of rabies virus in a suitable 
target cells. Adhesion to target cells required rabies 
virus to infect target cells. Antibodies against this 
protein can prevent infection and neutralize the virus 
enters the body susceptible host.1 Therefore, the 
antibody titers obtained in this study have reflected 
more or less neutralizing antibodies induced by the 
above three types of vaccines. According to WHO 
(1997) that a protective antibody titer was ≥ 0.5 IU / 
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ml.2 In this study, three types of vaccines applied were 
able to induce antibodies with titer exceed the 
number endorse by WHO. However, at the end the 
titer was declined and some of them below this value.  
There are differences in pattern of antibody 
responses induced by oral and injection vaccine. In 
oral vaccines, its antibodies appear and achieve 
maximum peak and declined more slowly than the 
inject able vaccine. Antiviral antibody titers of dog 
vaccinated with injection rabies vaccine gain 
maximum peak in the third week or day-21 after 
vaccination, while antibody titers in dogs vaccinated 
with the oral vaccine increase in the eighth weeks or 
on days 56 after vaccination. This difference appears 
because of the preparations different of virus used in 
oral and injectable vaccines. Injectable vaccine 
contains inactive virus which does not require 
replication to induce humoral immunity in dogs, while 
the oral vaccine containing active virus that must be 
replicated before they were able to induce humoral 
immunity in dogs vaccinated.3-5  
The humoral immune response mediated by B 
cells is assisted by a helper T cell type 2 (T-helper-
2/Th-2). Injectable vaccine virus that has been 
deactivated will be processed quickly by the antigen 
presenter cells (antigen presenting cells / APC) and 
then presented via MHC-2 molecules to the cell Th-2 
(CD4+) so that the cells are activated. The cell Th-2 is 
activated will be trigger B cells to divide and 
differentiate into plasma cells to produce antibodies 
and memory cells as a backup if there is a subsequent 
infection.6 The sooner the vaccine antigen is processed 
by the immune system, the sooner the response 
appeared.  
Observations from week to week show that the 
oral vaccine able to induce humoral immunity that last 
longer than the parenteral vaccine. For example at 
weeks 12 or on days 84 after vaccination it was able to 
induce antibody titer higher than oral vaccine with a 
vaccine injection. In oral vaccine containing active 
virus will bully humoral immune system after the virus 
replicates.6 The existence of replication induce the 
immune  last longer and also represents the excess of 
the oral vaccine compared to vaccine injection.  
For parenteral vaccine type, in this case and 
Rabivet Rabisin Supra 92, averaging humoral antibody 
titers increased sharply at day 21 after vaccination. 
This is different from the tiny fraction of that stated in 
the literature that the striking peak antibody titers of 
between three months and six months after 
vaccination.7 Research also showed that the humoral 
antibody response after vaccination in dogs 
experiments in the laboratory is always better than in 
pet dogs.8 Therefore, it should be anticipated that 
laboratory-scale research may differ from its 
application in the field.  
Antibody titer by vaccine induces Rabisin and 
Rabivet 92 Supra visible decline started at day 56, day 
84 and day-to-119. Especially for flats Rabisin vaccine 
antibody titers at day-119 is still above 0.5 IU/ml 
according to OIE or WHO reference, while for the 
vaccine Rabivet Supra 92, the average antibody titer 
humoralnya has been below the level of 0.5 IU / ml. 
These results indicate that vaccination with the 
vaccine Rabivet 92 Supra requires revaccination 
(booster) is faster than the vaccine Rabisin. Generally, 
the first on the pet vaccination induces lower antibody 
titers and decreased rapidly compared with the 
second vaccination or more.10 According to Lambot et 
al., (2001) rabies vaccine dosing only once on the wolf 
not only produced fewer memory cells, but also takes 
a long time to maintain the memory cells and 
preparation to protect the body from virus attacks 
challange.13 
 
CONCLUSION 
SAG2 oral vaccine is safe and can be used as an 
alternative vaccine to combat rabies in animals, 
especially Kampung dogs. SAG2 oral vaccine can be 
recommended for use in order to control rabies cases 
in Indonesia 
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